Skip to main content

Main navigation

  • About
    • Members
    • Our Team
    • Annual Report
    • Rutgers-NPC Health Policy & Communications Fellowship
    • NPC Summer Scholars
    • Contact Us
  • Topics
    • Health Spending
      • IRA & Medicare Drug Price Negotiation
      • 340B Drug Pricing Program
      • Understanding Health Spending
      • Low-Value Care
      • Health Spend Management
    • Value Assessment
      • Value Assessment Frameworks
      • Value Assessment Methods
      • Elements of Value
    • Alternative Payment Models
      • Value-Based Contracts
      • Regulatory Barriers & Challenges
      • Paying for Cures
      • Accountable Care Organizations
      • Bundled Payments
      • Health Care Quality Measures
      • Clinical Pathways
    • Patient-Centered Formulary & Benefit Design
      • High-Deductible Health Plans
      • Value-Based Insurance Design
      • Utilization Management & Step Therapy
      • Formulary Development
      • Patient Cost Sharing
      • Individual Treatment Effects & Personalized Access
    • Evidence for Decision Making
      • Real-World Data
      • Real-World Evidence
      • Good Practices for Evidence
    • Biopharma Innovation
      • Impact on Outcomes & Spending
  • Resources
    • Research
    • Fact Sheets
    • Policy & Evidence Briefs
    • Letters & Comments
    • E.V.I.dently Today Blog
    • Newsletters
    • Events
    • CER Daily Newsfeed®
    • Press Room
      • NPC in the News
      • NPC Press Releases
    • Videos and Graphics
    • Stakeholder Resources
      • For Employers
      • For Patient Organizations
      • Going Below The Surface
  • Get Involved
    • Become a Member
    • Submit a Research Proposal
    • Start a Career
National Pharmaceutical Council

Offscreen menu

User account menu

  • Member Resources

Case Study: Using Health Care Spending Guiding Principles to Evaluate "Will Reducing Drug Prices Slow Innovation"

  • Read more about Case Study: Using Health Care Spending Guiding Principles to Evaluate "Will Reducing Drug Prices Slow Innovation"

New Moves to Shine More Light Into an Opaque Drug Pricing System

  • Read more about New Moves to Shine More Light Into an Opaque Drug Pricing System

Drug Price Regulation Trade-offs: Real or Imagined?

  • Read more about Drug Price Regulation Trade-offs: Real or Imagined?

Drug Price Controls in Medicare Part D: Not a Remedy for More Than 5 Million Medicare Beneficiaries

  • Read more about Drug Price Controls in Medicare Part D: Not a Remedy for More Than 5 Million Medicare Beneficiaries

Patient-Centered Guiding Principles for Reforming Health Care to Address Rising Health Care Spending

  • Read more about Patient-Centered Guiding Principles for Reforming Health Care to Address Rising Health Care Spending

Patient-Centered Guiding Principles for Evaluating Health Care Spending

  • Read more about Patient-Centered Guiding Principles for Evaluating Health Care Spending

Health Care Spending Guiding Principles

  • Read more about Health Care Spending Guiding Principles

NPC in Chain Drug Review: Fostering a More Informed Drug Pricing Conversation

  • Read more about NPC in Chain Drug Review: Fostering a More Informed Drug Pricing Conversation

NPC in RealClearPolicy: Price Setting Bill Is No Panacea for Patients

  • Read more about NPC in RealClearPolicy: Price Setting Bill Is No Panacea for Patients

Digging Deeper Into Health Spending | November 2021

  • Read more about Digging Deeper Into Health Spending | November 2021

Pagination

  • Next page
  • Page 6
  • Next page
Subscribe to Health Spending

Let's stay in touch.

Subscribe to our newsletter.
© 2026 NPC. All rights reserved.

Footer Menu

  • Accessibility
  • Privacy Policy
  • Terms of Use
  • Contact Us

Footer Social Links Menu

  • Twitter image/svg+xml
  • Linkedin
  • Youtube